Valeant Pharmaceuticals (NYSE:VRX) impressed investors today by announcing strong guidance for 2014. The drugmaker expects earnings and revenue to come in about 40% higher than the previous year. Shares climbed as much as 10% in trading, hitting a new 52-week high.

Tim Hanson of Motley Fool Asset Management likes Valeant's lofty aspirations. He sees the company increasing cash flow by integrating its purchase of Bausch & Lomb, while revenue growth will likely come from new pharmaceutical products as well as another successful acquisition. 

However, Tim thinks the stock looks a little pricey at the moment. Furthermore, Valeant depends on acquisitions for growth, and though it boasts a good track record there, that's not always guaranteed.

Get our No. 1 stock pick for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of the latter. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Erin Kennedy and Tim Hanson have no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.